ProPhase Labs Announces Full USPTO Approval for Issuance of U.S. Patent Protecting Esophageal Adenocarcinoma Risk Assessment
- U.S. Patent No. 12379378-B2 protects biomarker-driven systems and methods to assess progression risk in Barrett's esophagus and esophageal adenocarcinoma; issuance follows the successful BE-Smart ™ test validation (>95% technical success) and, together with BE-Smart's demonstrated compatibility with both brush and forceps biopsies, supports earlier detection.
- 08/12/2025
|
ProPhase Labs Inc. to Present Second Quarter 2025 Financial Results on August 13, 2025
- UNIONDALE, NY, Aug. 11, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, announced today that they will be presenting second quarter 2025 financial results on a virtual conference call hosted by Renmark Financial on August 13, 2025, at 2:00 pm EDT. A press release detailing these results will be issued prior to the virtual conference call.
- 08/11/2025
|
ProPhase Labs Announces Special Meeting of Shareholders and Filing of Preliminary Proxy Statement
- Proxy Sets Company on a Path to Attract the Optimal Crypto Treasury Strategy Increase in Authorized Shares to 1 Billion Would Position the Company to Attract Industry-Leading Market Participants and High-Value Crypto Treasury Transactions UNIONDALE, NY, July 29, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, will hold a Special Meeting of Shareholders on August 29, 2025, at 4:00 p.m. Eastern Time at 273 Merrick Road, Lynbrook, NY 11563.
- 07/29/2025
|
ProPhase Labs Announces Closing of $3 Million Senior Secured Convertible Notes Financing
- Financing provides bridge to multiple potentially significant liquidity events and crypto strategies UNIONDALE, NY, July 23, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), (the "Company" or "ProPhase") today announced the closing of a private placement financing with two investors for $3 million in senior secured convertible notes with accompanying warrants to purchase shares of common stock. The notes were issued with a 20% original issue discount, are secured by the Company and subsidiary assets, and may be prepaid at any time without penalty.
- 07/23/2025
|
ProPhase Labs Board of Directors Authorizes Management to Explore Strategic Reverse Merger and Approves Crypto Treasury Initiative
- UNIONDALE, NY, July 21, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today announced that its Board of Directors has unanimously authorized the Company's executive team to explore a potential reverse merger transaction with a digital asset-focused operating company to supplement its existing businesses. The Board has also approved a strategic treasury initiative involving the acquisition and long-term holding of select digital assets, including Bitcoin.
- 07/21/2025
|
ProPhase Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule
- UNIONDALE, NY, June 26, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today announced that it has received an extension of 180 calendar days (the "Extension Notice") from The Nasdaq Stock Market LLC ("Nasdaq") to regain compliance with the Nasdaq's minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq (the "Bid Price Requirement"), following the expiration of the initial 180 calendar days period to regain compliance on June 24, 2025. NASDAQ stated that it based its determination to grant the extension based on the Company meeting all other applicable requirements for initial listing on the Capital Market with the exception of the bid price requirement.
- 06/26/2025
|
ProPhase Labs Announces Successful Study Demonstrating Performance of BE-Smart™ Test in Detecting Esophageal Cancer
- BE-Smart represents a significant advance in diagnosis and management of Esophageal disease that affects an estimated 60 million people in the United States
- 06/17/2025
|
52,394 Shares in ProPhase Labs, Inc. (NASDAQ:PRPH) Acquired by Squarepoint Ops LLC
- Squarepoint Ops LLC bought a new stake in shares of ProPhase Labs, Inc. (NASDAQ:PRPH – Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 52,394 shares of the company’s stock, valued at approximately $40,000. Squarepoint Ops LLC owned about 0.22% of ProPhase Labs as of its most recent filing with the SEC. A number of other large investors have also recently bought and sold shares of the stock. Warberg Asset Management LLC purchased a new position in shares of ProPhase Labs during the 4th quarter worth $77,000. Renaissance Technologies LLC lifted its stake in shares of ProPhase Labs by 33.2% during the 4th quarter. Renaissance Technologies LLC now owns 286,485 shares of the company’s stock worth $217,000 after purchasing an additional 71,375 shares during the period. Perritt Capital Management Inc lifted its stake in shares of ProPhase Labs by 129.1% during the 4th quarter. Perritt Capital Management Inc now owns 190,000 shares of the company’s stock worth $144,000 after purchasing an additional 107,068 shares during the period. Geode Capital Management LLC lifted its stake in shares of ProPhase Labs by 26.6% during the 4th quarter. Geode Capital Management LLC now owns 203,528 shares of the company’s stock worth $154,000 after purchasing an additional 42,793 shares during the period. Finally, HighTower Advisors LLC lifted its stake in shares of ProPhase Labs by 32.2% during the 4th quarter. HighTower Advisors LLC now owns 236,781 shares of the company’s stock worth $179,000 after purchasing an additional 57,736 shares during the period. Institutional investors and hedge funds own 9.45% of the company’s stock. ProPhase Labs Trading Down 1.9% Shares of ProPhase Labs stock opened at $0.35 on Wednesday. ProPhase Labs, Inc. has a fifty-two week low of $0.22 and a fifty-two week high of $4.84. The firm has a market cap of $14.54 million, a PE ratio of -0.28 and a beta of -0.43. The business’s fifty day moving average is $0.32 and its two-hundred day moving average is $0.46. The company has a quick ratio of 1.33, a current ratio of 1.47 and a debt-to-equity ratio of 0.48. ProPhase Labs (NASDAQ:PRPH – Get Free Report) last issued its quarterly earnings results on Tuesday, May 20th. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.06. ProPhase Labs had a negative return on equity of 62.92% and a negative net margin of 217.64%. The company had revenue of $1.43 million for the quarter, compared to analyst estimates of $2.45 million. Analysts anticipate that ProPhase Labs, Inc. will post -1.27 earnings per share for the current year. Analysts Set New Price Targets Separately, Wall Street Zen assumed coverage on ProPhase Labs in a research note on Tuesday, February 25th. They set a “sell” rating on the stock. Get Our Latest Analysis on PRPH ProPhase Labs Company Profile (Free Report) ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. See Also Five stocks we like better than ProPhase Labs Low PE Growth Stocks: Unlocking Investment Opportunities AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway How Investors Can Find the Best Cheap Dividend Stocks Casey’s Surges on Strong Q4, More Gains Likely Ahead 3 Stocks to Consider Buying in October Government Mandate Sends eVTOL Stocks Flying Want to see what other hedge funds are holding PRPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ProPhase Labs, Inc. (NASDAQ:PRPH – Free Report).
- 06/11/2025
|
ProPhase Labs Announces Formation of Clinical Science Advisory Board to Accelerate Commercialization of BE-SmartTM Esophageal Disease Diagnostic Platform
- UNIONDALE, NY, June 06, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today announced the formation of its Clinical Science Advisory Board to support the clinical adoption and commercialization of its breakthrough BE-SmartTM molecular test for esophageal disease. The advisory board will provide expert strategic guidance as ProPhase leads the regulatory and commercialization pathway for BE-Smart, with the goal of establishing a new clinical and economic standard in the early detection and management of esophageal cancer risk.
- 06/06/2025
|
ProPhase Labs, Inc. (PRPH) Q1 2025 Earnings Call Transcript
- ProPhase Labs, Inc. (NASDAQ:PRPH ) Q1 2025 Earnings Conference Call May 20, 2025 10:00 AM ET Company Participants Noella Alexander-Young - Virtual Event Moderator, Renmark Financial Communications Ted Karkus - Chief Executive Officer Noella Alexander-Young Hello, and good morning everyone. Welcome to today's presentation.
- 05/20/2025
|
ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2025
- Highlights Multiple Significant Potential Liquidity Events Anticipated Within the Next Few Months Completes Significant Reductions in Overhead and Expenses BE-Smart Esophageal Cancer Test Study has been Submitted in the Journal of Clinical Gastrointestinal Hepatology Company to hold a virtual conference call Tuesday, May 20, 2025, at 10:00 AM ET GARDEN CITY, NY, May 20, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today reported its financial and operational results for Q1 ended March 31, 2025, and outlined significant strategic corporate developments. Ted Karkus, CEO of ProPhase Labs, will present to shareholders today, May 20, 2025, at 10:00 a.m.
- 05/20/2025
|
ProPhase Labs Inc. to Present First Quarter 2025 Financial Results on May 20, 2025
- GARDEN CITY, NY, May 13, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, announced today that they will be presenting first quarter 2025 financial results on a virtual conference call hosted by Renmark Financial on May 20, 2025, at 10:00 am EDT. Ted Karkus, CEO, looks forward to providing shareholders with an update on several positive activities, including the initiative to sell the Company's wholly owned subsidiary, Nebula Genomics, and the Crown Medical Collections initiative to collect tens of millions of dollars in accounts receivable.
- 05/13/2025
|
ProPhase Labs, Inc. (PRPH) Q4 2024 Earnings Call Transcript
- ProPhase Labs, Inc. (NASDAQ:PRPH ) Q4 2024 Earnings Conference Call March 31, 2025 11:00 AM ET Company Participants Noella Alexander-Young - Virtual Event Moderator, Renmark Financial Communications Ted Karkus - Chief Executive Officer Conference Call Participants Noella Alexander-Young Hello and good morning, everyone. Welcome to today's presentation.
- 03/31/2025
|
ProPhase Labs, Inc. Announces Financial Results for the Year Ended December 31, 2024
- Company to Accelerate BE-Smart Commercialization as a Cash-Pay Diagnostic Significantly reduces overhead, improves margins heading into Q2 2025 Company to hold a conference call Monday, March 31, 2025, at 11:00 AM EST GARDEN CITY, NY, March 31, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, today reported its financial and operational results for the full-year ended December 31, 2024 and outlined strategic corporate developments aimed at realigning the Company for sustained long-term growth, profitability, and strategic focus. Ted Karkus, CEO of ProPhase Labs, will present to shareholders today, March 31, 2025, at 11:00 a.m.
- 03/31/2025
|
ProPhase Labs Inc. to Present 2024 Year End Financial Results on March 31, 2025
- GARDEN CITY, NY, March 27, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, today announced that they will be presenting full year 2024 financial results, and a review of current Company strategy, on a virtual conference call hosted by Renmark Financial on March 31, 2025 at 11:00 AM EST. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event.
- 03/27/2025
|
ProPhase Labs to Present at the Investor Summit Virtual on March 11
- GARDEN CITY, NY, March 07, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and consumer products company, today announced that Ted Karkus, CEO, will be presenting at this year's Investor Summit Virtual on March 11th.
- 03/07/2025
|
Bears are Losing Control Over ProPhase Labs (PRPH), Here's Why It's a 'Buy' Now
- ProPhase Labs (PRPH) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
- 03/05/2025
|
Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)
- New York, NY, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on ProPhase Labs Inc. (NASDAQ: PRPH). The update note includes information on ProPhase's business model, services offered, industry outlook, financial results, management commentary, and risks.
- 02/26/2025
|
ProPhase Labs Examines Strategic Opportunities to Leverage Its DTC Multi-Media Infrastructure with Telehealth Physician Networks for Prescription Drugs
- Company Announces Ongoing Strategic Cost Cutting to Focus Resources on new DTC Marketing Initiatives to Drive Growth and Profitability Dispels rumors of an Investment Bank initiating a Capital Raise GARDEN CITY, NY, Feb. 25, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and consumer products company provides a Company update and schedules a conference call for later today. Following the hiring of Stu Hollenshead, several new strategic opportunities have emerged for the Company to capitalize on its DTC multi-media expertise and infrastructure.
- 02/25/2025
|
ProPhase Labs Announces Excellent Progress with Crown Medical Collections Targeting Over $50 Million in Net Near-Term Cash Recovery from COVID-19 Receivables
- Company Actively Pursuing Strategic Alternatives Including the Potential Sale of Nebula Genomics and DNA Complete to Unlock Immediate Cash GARDEN CITY, NY, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and consumer products company, is focused on immediate cash generation through two key initiatives: strategic alternatives including a potential sale of its genomics assets and the aggressive collection of outstanding COVID-19 receivables. These initiatives are expected to generate significant liquidity starting in the next few months and strengthen the company's balance sheet.
- 02/20/2025
|
ProPhase Labs hires Stuart Hollenshead as COO, the former COO and CBO of Barstool Sports
- GARDEN CITY, NY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and consumer products company, today announced the appointment of Stu Hollenshead as Chief Operating Officer, marking a pivotal step in the company's expansion into consumer-centered health and wellness products. As COO, Hollenshead will focus on accelerating ProPhase Labs' consumer-facing strategy, leveraging his deep expertise in direct-to-consumer growth, subscription models, digital marketing, and audience monetization to position the company as a leader in science-backed health solutions.
- 02/18/2025
|
ProPhase Labs, Inc. (PRPH) Q3 2024 Earnings Call Transcript
- ProPhase Labs, Inc. (NASDAQ:PRPH ) Q3 2024 Results Conference Call November 13, 2024 11:00 AM ET Company Participants Noella Alexander-Young - Renmark Financial Communications Ted Karkus - Chief Executive Officer Noella Alexander-Young Welcome to today's presentation. My name is Noella Alexander-Young, Virtual Event Moderator here at Renmark Financial Communications.
- 11/15/2024
|
ProPhase Labs, Inc. (PRPH) Reports Q3 Loss, Tops Revenue Estimates
- ProPhase Labs, Inc. (PRPH) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.30 per share a year ago.
- 11/13/2024
|
ProPhase Labs Inc. to Present Third Quarter 2024 Financial Results on November 13, 2024
- GARDEN CITY, NY, Nov. 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and diagnostics company, today announced that they will be presenting third quarter 2024 financial results on a virtual conference call hosted by Renmark Financial on November 13, 2024 at 11:00 AM EST. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event.
- 11/11/2024
|
ProPhase Labs Announces Pricing of Public Offering of Common Stock
- GARDEN CITY, NY, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics and diagnostics company, today announced the pricing of its underwritten public offering of 4,170,000 shares of common stock. Each share of common stock is being sold at a public offering price of $0.72 per share, for gross proceeds of approximately $3 million, before deducting underwriting discounts, and offering expenses. All of the shares are being offered by the Company. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 625,500 shares of common stock at the public offering price less discounts, to cover over-allotments. The offering is expected to close on November 12, 2024, subject to satisfaction of customary closing conditions.
- 11/07/2024
|
ProPhase Labs Announces Positive Updates on Strategic Initiatives Company Anticipates Multiple Liquidity Events in H1 2025
- Projections for Pharmaloz Manufacturing: Approximately $16-17 Million in Revenue, $6-7 Million in Pre-Tax Earnings for 2025
- 10/17/2024
|
Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)
- NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, an equity research firm with a focus on small capitalization public companies has released an Update Note on ProPhase Labs Inc. (NASDAQ: PRPH). The update note includes information on the ProPhase's business model, services, industry, financial results, valuation, and risks and contains our most recent research and analysis of the company.
- 08/27/2024
|
ProPhase Labs to Present at August 20th Virtual Investor Summit Microcap Event
- GARDEN CITY, NY, Aug. 19, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today announced that it will be presenting at the Virtual Investor Summit Microcap Event. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.
- 08/19/2024
|
ProPhase Labs, Inc. (PRPH) Q2 2024 Earnings Call Transcript
- ProPhase Labs, Inc. (NASDAQ:PRPH ) Q2 2024 Earnings Conference Call August 14, 2024 11:00 AM ET Company Participants Noella Alexander-Young - Renmark Financial Communications Ted Karkus - Chief Executive Officer Conference Call Participants Hunter Diamond - Diamond Equity Noella Alexander-Young Hello and good morning, everyone. Welcome to today's presentation.
- 08/14/2024
|
PROPHASE LABS INC. TO PRESENT SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 14
- GARDEN CITY, NY, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), announced today that they will be presenting second quarter 2024 financial results on a virtual conference call hosted by Renmark Financial on August 14, 2024 at 11:00 am EDT. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event.
- 08/07/2024
|
ProPhase Labs Announces Update on Pharmaloz Manufacturing, Inc. Progress
- PMI Revenues and Earnings Projected to Grow Significantly in the Second Half of 2024 and Full Year 2025. New Strategic Initiatives for PMI Create Significant Opportunities for Liquidity and Value Creation Garden City, NY, July 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today reported that Pharmaloz Manufacturing, Inc. (“PMI”), its wholly-owned subsidiary, is projecting significant revenues and earnings growth for the second half of 2024 and the entire year of 2025.
- 07/11/2024
|
ProPhase Labs, Inc. (PRPH) Q1 2024 Earnings Call Transcript
- ProPhase Labs, Inc. (NASDAQ:PRPH ) Q1 2024 Earnings Conference Call May 9, 2024 11:00 AM ET Company Participants Noella Alexander-Young - Renmark Financial Communications Ted Karkus - Chief Executive Officer Conference Call Participants Noella Alexander-Young Welcome to today's presentation. My name is Noella Alexander-Young, Virtual Event Moderator here at Renmark Financial Communications.
- 05/09/2024
|
ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives. - Updated
- Pharmaloz Manufacturing explores strategic alternatives, including potential sale. Company announces major strategic AI initiative, Project ZenQ-AI, leveraging its massive global genomics database and patented discoveries in its BE-Smart Esophageal Cancer Diagnostic Test.
- 05/09/2024
|
ProPhase Labs, Inc. (PRPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- ProPhase Labs (PRPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/02/2024
|
ProPhase Labs to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024
- Garden City, NY, April 25, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a biopharma, genomics and diagnostics Company, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 at 11:30 am PST, 2:30 pm EST. Ted Karkus, CEO, will be hosting the presentation and answering questions at the conclusion.
- 04/25/2024
|
ProPhase Labs Unveils Project ZenQ-AI
- Leveraging ProPhase Labs' AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development.
- 04/16/2024
|
PRISM MarketView – Biotech Breakfast
- Mobile-Health Network Solutions (MNDR) IPOs; Q32 Bio Surges; EMA Concludes GLP-1 Drugs Not Associated with Suicidal Thoughts New York, N.Y., April 15, 2024 – PRISM MarketView – Healthcare equities finished lower on Friday, in line with broad declines across the market.
- 04/15/2024
|
ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024
- Garden City, NY, April 10, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today reported its progress on the commercialization of its breakthrough BE-Smart test for esophageal cancer. The Company is aiming for commercial launch in the second half of 2024.
- 04/10/2024
|
ProPhase Labs Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Garden City, NY, April 01, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biopharma, genomics, and diagnostics company, today announced that it has granted an inducement stock option to purchase up to 50,000 shares of the Company's common stock to Lance Bisesar, who recently joined the Company as Controller. This award was made in accordance with the employment inducement award exemption provided by Nasdaq Rule 5635(c)(4) and was therefore not awarded under the Company's stockholder approved equity plan. The option award will vest as follows, contingent upon continued service: 25% will vest on each of the next four anniversaries of the grant date. The options will have a strike price of $6.20 per share and will be exercisable for a period of 7 years.
- 04/01/2024
|
ProPhase Labs, Inc. (PRPH) Q4 2023 Earnings Call Transcript
- ProPhase Labs, Inc. (PRPH) Q4 2023 Earnings Call Transcript
- 03/15/2024
|
ProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic Initiatives
- Nebula Genomics secures major international B2B deal – Additional significant B2B deals in final stages Ahead of schedule, Pharmaloz Manufacturing accelerates capacity expansion – set for rapid revenue and profit growth Completes full transition and right sized operation in Q4 from clinical lab to cutting edge genomics lab Company to hold a conference call Friday March 15, 2024, at 11:00 AM ET Garden City, NY, March 15, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biopharma, genomics, and diagnostics company, today reported its financial and operational results for the full-year ended December 31, 2023. The end of 2023 marked a period of significant capacity expansion and growth for Pharmaloz Manufacturing Inc. (PMI) as well as a pivotal transformation for the Company, transitioning from a clinical laboratory framework to a leader in whole genome sequencing.
- 03/15/2024
|
Down 34% and 57%, Wall Street Says These 2 Stocks Will Gain 230%
- In the volatile world of trading and investing, where fortunes can be made or lost in the blink of an eye, two companies caught the attention of Wall Street despite their recent struggles over the last year.
- 03/12/2024
|
PROPHASE LABS TO PRESENT 2023 YEAR END FINANCIAL RESULTS ON MARCH 15, 2024
- GARDEN CITY, NY, March 08, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), announced today that they will be presenting full year 2023 financial results on a virtual conference call hosted by Renmark Financial on March 15, 2024 at 11:00 am EDT. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event.
- 03/08/2024
|
ProPhase Labs Announces Preliminary Positive Results for Dietary Supplement Equivir
- Commercialization of Equivir anticipated after second trial is completed in Q2, 2024 Garden City, NY, Feb. 14, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics and diagnostics company, today announced positive preliminary results from its Equivir dietary supplement comprehensive trial. Preliminary results indicate that this innovative OTC dietary supplement has the potential to support and maintain immunity, which – if confirmed at the end of the clinical trial program – may help reduce both the frequency and severity of upper respiratory illnesses including the common cold, flu, and Covid-19.
- 02/14/2024
|
Pharmaloz Manufacturing Accelerates Expansion, Improves Pricing, Boosts Profitability and Secures New Contracts
- Pharmaloz Wins Two New Contracts in January that are Anticipated to Significantly Increase Lozenge Revenues and Profitability Company in Late-Stage Discussions with Two Additional Large Global Brands Which, if Consummated, Could more than Triple Run-Rate of Revenues Before Year-End 2024
- 01/23/2024
|
ProPhase Labs, Inc. (PRPH) Q3 2023 Earnings Call Transcript
- ProPhase Labs, Inc. (NASDAQ:PRPH ) Q3 2023 Earnings Conference Call November 9, 2023 11:00 AM ET Company Participants Ted Karkus - Chairman and CEO Conference Call Participants Adam Waldo - Lismore Partners Yi Chen - H.C. Wainwright Hunter Diamond - Diamond Equity Dennis Waldman - Barrett Productions Operator Good day and welcome the ProPhase Labs Incorporated Third Quarter 2023 Financial Results and Corporate Update.
- 11/09/2023
|
ProPhase Labs to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 9, 2023 at 11:00 a.m. Eastern Time
- GARDEN CITY, NY, Nov. 02, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics, therapeutics and diagnostics company, will hold a conference call on Thursday, November 9, 2023, at 11:00 a.m. Eastern time to discuss its results for the third quarter ended September 30, 2023 and provide a business update. A press release detailing these results will be issued prior to the call.
- 11/02/2023
|
ProPhase Labs Announces Substantial Growth Expectations for Pharmaloz Manufacturing Subsidiary due to Skyrocketing Demand for Pharmaloz Output.
- Pharmaloz plan is to build capacity with a goal to attain a revenue run-rate of $60 to $80 million by year-end 2024, with 20-25% pre-tax net margins and a goal for additional growth thereafter.
- 10/17/2023
|
ProPhase Labs to Present at The ThinkEquity Conference
- GARDEN CITY, NY, Oct. 12, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics, therapeutics and diagnostics company, today announced it will be participating in The ThinkEquity Conference, which will take place on October 19, 2023 at The Mandarin Oriental Hotel in New York.
- 10/12/2023
|
ProPhase Labs, Inc. (PRPH) Q2 2023 Earnings Call Transcript
- ProPhase Labs, Inc. (NASDAQ:PRPH ) Q2 2023 Earnings Conference Call August 10, 2023 11:00 AM ET Company Participants Ted Karkus - Chairman and CEO Conference Call Participants Adam Waldo - Lismore Partners Dennis Waldman - Barrett Productions Yi Chen - H.C. Wainwright Operator Good day, and welcome to the ProPhase Labs Second Quarter 2023 Financial Results and Corporate Update.
- 08/12/2023
|
ProPhase Labs, Inc. (PRPH) Reports Q2 Loss, Lags Revenue Estimates
- ProPhase Labs, Inc. (PRPH) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to earnings of $0.40 per share a year ago.
- 08/10/2023
|
ProPhase Labs Announces Updated Conference Call Dial-in Information for Thursday August 10, 2023 at 11:00 a.m. Eastern Time for Second Quarter 2023 Financial Results Call.
- Garden City, NY, Aug. 10, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) Conference Call and Webcast Details Management will host a conference call at 11:00 AM ET, Thursday, August 10, 2023, to provide an update on corporate developments and review financial results. Following management's formal remarks, there will be a question-and-answer session.
- 08/10/2023
|
ProPhase Labs to Host Second Quarter 2023 Financial Results Conference Call on Thursday, August 10, 2023 at 11:00 a.m. Eastern Time
- GARDEN CITY, NY, Aug. 02, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics, therapeutics and diagnostics company, will hold a conference call on Thursday, August 10, 2023, at 11:00 a.m. Eastern time to discuss its results for the second quarter ended June 30, 2023 and provide a business update. A press release detailing these results will be issued prior to the call.
- 08/02/2023
|
Navidea Biopharmaceuticals rejects ProPhase Labs offer
- Navidea Biopharmaceuticals Inc. NAVB, -2.38% announced Friday that it had rejected an unsolicited ProPhase Labs Inc. PRPH, +0.08% offer for certain Navidea assets, saying the proposal undervalues Navidea and is not in the best interest of shareholders. ProPhase, a biotech, genomics and diagnostics company, said in a release Thursday that on June 8 it had offered $7 million in cash or $9.1 million in common stock for the assets, with the cash offer equivalent to over two times the then-current market cap of Navidea.
- 06/30/2023
|
ProPhase Labs Continues To Make The Right Moves - Reiterate Strong Buy
- ProPhase Labs thrived in the Covid era and then wisely used the gains to invest in new testing capabilities including whole genome sequencing and a new esophageal cancer test. The capabilities will allow PRPH to greatly increase its currently addressable market, and, if all goes well, within a year and a half revenues should start expanding precipitously. PRPH's finances and operational experience should enable it to get to the developmental finish line without needing to execute any dilutive financings.
- 06/11/2023
|
ProPhase Labs to Present at the Diamond Equity Research Emerging Growth Invitational on Tuesday, June 13, 2023
- Garden City, NY, June 07, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next generation biotech, genomics and diagnostics company, today announced that management will present at the Diamond Equity Research Emerging Growth Invitational virtual investor conference taking place Tuesday, June 13th at 1:00 pm Eastern time.
- 06/07/2023
|
ProPhase Labs, Inc. (PRPH) Surges 8.5%: Is This an Indication of Further Gains?
- ProPhase Labs, Inc. (PRPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 05/03/2023
|
7 Small-Cap Biotech Stocks with Massive Potential
- While unproven biotechnology firms almost always carry significant risks, small-cap biotech stocks in particular typically impose jaw-dropping volatility. Along with the usual risk of clinical disappointments or outright failures, these speculative enterprises are obviously less funded.
- 04/27/2023
|
ProPhase Labs, Inc. (PRPH) Soars 7.5%: Is Further Upside Left in the Stock?
- ProPhase Labs, Inc. (PRPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
- 04/10/2023
|
ProPhase Labs: Lots Of Moving Pieces
- Medical diagnostic and testing concern ProPhase Labs, Inc. gets put in the spotlight today. ProPhase Labs, Inc. has seen huge revenue growth from Covid testing but is rapidly diversifying into other areas.
- 03/02/2023
|
ProPhase Labs to Present at the Planet MicroCap Showcase: VIRTUAL 2022 on Wednesday, December 7, 2022
- GARDEN CITY, NY, Nov. 30, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that it will be presenting at the Planet MicroCap Showcase: VIRTUAL 2022 on Wednesday, December 7, 2022 at 2:30 pm EST. Ted Karkus, CEO, will be hosting the presentation.
- 11/30/2022
|
ProPhase Labs Discloses 8.4% Position in LTRN / Lantern Pharma After Q3 Results
- Fintel reports that ProPhase Labs, Inc. has filed a 13G form with the SEC disclosing ownership of 910,000 shares of Lantern Pharma Inc. (LTRN). This represents 8.4% of the company.
- 11/22/2022
|
ProPhase Labs, Inc. (PRPH) Q3 2022 Earnings Call Transcript
- ProPhase Labs, Inc. (NASDAQ:PRPH ) Q3 2022 Earnings Conference Call November 10, 2022 11:00 AM ET Company Participants Ted Karkus – Chairman and Chief Executive Officer Conference Call Participants Fred McDonald – Private Investor Yi Chen – H.C. Wainwright Dennis Waldman – Barrett Productions, LLC Patrick Patterson – Investor Operator Good morning, afternoon, evening, and welcome to the ProPhase Labs Third Quarter 2022 Financial Results Conference Call.
- 11/10/2022
|
ProPhase Labs, Inc. (PRPH) Q3 Earnings Miss Estimates
- ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of -60% and 28.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/10/2022
|
ProPhase Labs to Present at Investor Summit Group's Q4 Conference
- GARDEN CITY, NY, Nov. 07, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced it will be participating in the Q4 Investor Summit Conference, which will take place on November 14, 2022 in New York, New York. ProPhase Labs' CEO and Chairman of the Board of Directors, Ted Karkus will be presenting at 3:00 PM ET on November 14, 2022.
- 11/07/2022
|
ProPhase Labs to Host Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022 at 11:00 a.m. Eastern Time
- GARDEN CITY, NY, Nov. 04, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, will hold a conference call on Thursday, November 10, 2022 at 11:00 a.m. Eastern time to discuss its results for the third quarter ended September 30, 2022. A press release detailing these results will be issued prior to the call.
- 11/04/2022
|
3 Small-Cap Pharma Stocks For A 2022 Melt-Up
- This year's bear markets have resulted in a fall in portfolio performance. Healthcare, the second best sector this year, is defensive and has stood the test of time. The Fed's stance and volatile price swings that include declines of more than 20% in the major indexes are prompting investors to consider defensive investments.
- 10/27/2022
|
ProPhase Labs to Present at The ThinkEquity Conference
- GARDEN CITY, NY, Oct. 18, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced it will be participating in The ThinkEquity Conference, which will take place on October 26, 2022 at The Mandarin Oriental Hotel in New York, New York.
- 10/18/2022
|
ProPhase Labs: Small Cap Stock With Strong Fundamentals And Growth Potential
- ProPhase Labs released record breaking Q2 2022 results beating earnings expectations by $0.22 with EPS of $0.40. ProPhase Labs has surpassed earning expectations for the last three consecutive quarters.
- 10/13/2022
|
5 Big Winners as Dollar Strengthens on Fed Rate Hike
- A stronger dollar is a boon for Consolidated Water (CWCO), Ashford Hospitality Trust (AHT), BankFinancial (BFIN), LogicBio Therapeutics (LOGC) and ProPhase Labs (PRPH) that have high domestic exposure in terms of revenue generation.
- 09/27/2022
|
Are Medical Stocks Lagging ProPhase Labs (PRPH) This Year?
- Here is how ProPhase Labs, Inc. (PRPH) and Concert Pharmaceuticals (CNCE) have performed compared to their sector so far this year.
- 09/08/2022
|
ProPhase Labs to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 12-14, 2022 (HYBRID CONFERENCE)
- GARDEN CITY, NY, Sept. 06, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022 at 2:30 pm, Eastern Time. The conference is being held as a hybrid in-person/virtual event from September 12 to 14, 2022.
- 09/06/2022
|
Here's Why ProPhase Labs, Inc. (PRPH) is a Great Momentum Stock to Buy
- Does ProPhase Labs, Inc. (PRPH) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 08/25/2022
|
ProPhase Labs, Inc. (PRPH) CEO Ted Karkus on Q2 2022 Results - Earnings Call Transcript
- ProPhase Labs, Inc (NASDAQ:PRPH ) Q2 2022 Earnings Conference Call August 11, 2022 9:00 AM ET Company Participants Ted Karkus - Chairman & Chief Executive Officer Conference Call Participants Yi Chen - H.C. Wainwright Dennis Waldman - Barrett Productions, LLC Operator Good morning, and welcome to the ProPhase Labs Second Quarter 2022 Financial Results and Corporate Update.
- 08/11/2022
|
ProPhase Labs to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 11, 2022 at 11:00 a.m. Eastern Time
- GARDEN CITY, NY, Aug. 04, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, will hold a conference call on Thursday, August 11, 2022 at 11:00 a.m. Eastern time to discuss its results for the second quarter ended June 30,2022. A press release detailing these results will be issued prior to the call.
- 08/04/2022
|
Strength Seen in ProPhase Labs, Inc. (PRPH): Can Its 8% Jump Turn into More Strength?
- ProPhase Labs, Inc. (PRPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 07/26/2022
|
ProPhase Labs: A Growth Stock At An Attractive Valuation
- ProPhase Labs has expanded its in-house testing capabilities for the diagnostics of the new clinical chemistry, immunoassay, hematology, hemostasis, and urinalysis analyzers. ProPhase Labs has successfully obtained rights to commercialize two patented small molecule PIM kinase inhibitors in the licensing agreement with Global BioLife, Inc.
- 07/25/2022
|
5 Stocks With Recent Price Strength for a Steady Portfolio
- Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are USAK, FC, PRPH, DQ and CHEF.
- 07/11/2022
|
ProPhase Labs, Inc. (PRPH) Soars 9.1%: Is Further Upside Left in the Stock?
- ProPhase Labs, Inc. (PRPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 07/08/2022
|
ProPhase Labs: Healthcare Done Right
- 100% technical buy signals. 12 new highs and up 53.07% in the last month.
- 06/28/2022
|
ProPhase Labs, Inc. (PRPH) Surges 7.6%: Is This an Indication of Further Gains?
- ProPhase Labs, Inc. (PRPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 06/22/2022
|
Is ProPhase Labs (PRPH) Outperforming Other Medical Stocks This Year?
- Here is how ProPhase Labs, Inc. (PRPH) and RVL Pharmaceuticals PLC (RVLP) have performed compared to their sector so far this year.
- 06/13/2022
|
Has ProPhase Labs (PRPH) Outpaced Other Medical Stocks This Year?
- Here is how ProPhase Labs, Inc. (PRPH) and RVL Pharmaceuticals PLC (RVLP) have performed compared to their sector so far this year.
- 05/26/2022
|
ProPhase Labs, Inc. (PRPH) Moves to Strong Buy: Rationale Behind the Upgrade
- ProPhase Labs, Inc. (PRPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- 05/24/2022
|
ProPhase Labs to Present at the H.C. Wainwright 2022 Global Investment Conference
- May 23-26, 2022 (HYBRID CONFERENCE)
- 05/18/2022
|
ProPhase Labs, Inc. (PRPH) CEO Ted Karkus on Q1 2022 Results - Earnings Call Transcript
- ProPhase Labs, Inc. (NASDAQ:PRPH ) Q1 2022 Earnings Conference Call May 13, 2022 11:00 AM ET Company Participants Ted Karkus – Chairman & Chief Executive Officer Conference Call Participants Yi Chen – H.C. Wainwright & Co. Patrick Patterson – Home Robert Titus – MRT Industries Dennis Waldman – Barrett Productions Kyle Krueger – Apollo Capital Fred MacDonald – Private Investor Operator Good day and welcome to the ProPhase Labs First Quarter 2022.
- 05/13/2022
|
ProPhase Labs to Present at the Spring Into Action – Best Ideas Virtual Investor Conference
- Garden City, NY, May 11, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified diagnostics and genomics company, today announced that Chairman and CEO Ted Karkus will present at the Spring Into Action – Best Ideas Virtual Investor conference, which is being held virtually on May 17th-20th, 2022.
- 05/11/2022
|
ProPhase Labs to Host First Quarter 2022 Financial Results Conference Call on Friday, May 13, 2022 at 11:00 a.m. Eastern Time
- GARDEN CITY, NY, May 06, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified diagnostics and genomics company, will hold a conference call on Friday, May 13, 2022 at 11:00 a.m. ET to discuss its results for the first quarter ended March 31, 2022. A press release detailing these results will be issued prior to the call.
- 05/06/2022
|
ProPhase Labs to Present at the Planet MicroCap Showcase 2022 on Wednesday, May 4, 2022
- Garden City, NY, April 27, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified diagnostics and genomics company, today announced that Chairman and CEO Ted Karkus will present a corporate overview at the Planet MicroCap Showcase 2022 on Wednesday, May 4, 2022 at 1:30 PM EST.
- 04/27/2022
|
All You Need to Know About ProPhase Labs, Inc. (PRPH) Rating Upgrade to Strong Buy
- ProPhase Labs, Inc. (PRPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- 04/21/2022
|
3 Top Breakout Stocks to Buy for Remarkable Returns
- ProPhase Labs (PRPH), Hudson Technologies (HDSN) and YPF Sociedad Anonima (YPF) have been selected as the breakout stocks for today.
- 04/18/2022
|
ProPhase Labs, Inc. (PRPH) Soars 11.2%: Is Further Upside Left in the Stock?
- ProPhase Labs, Inc. (PRPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
- 04/05/2022
|
ProPhase Labs, Inc. (PRPH) CEO Ted Karkus on Q4 2021 Results - Earnings Call Transcript
- ProPhase Labs, Inc. (PRPH) CEO Ted Karkus on Q4 2021 Results - Earnings Call Transcript
- 03/30/2022
|
ProPhase Labs to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on Wednesday, March 30, 2022 at 11:00 a.m. Eastern Time
- GARDEN CITY, NY, March 24, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified company offering a range of services including diagnostic testing, genomics testing and contract manufacturing, will hold a conference call on Wednesday, March 30, 2022 at 11:00 a.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2021. A press release detailing these results will be issued prior to the call.
- 03/24/2022
|
ProPhase Labs to Present at the MicroCap Rodeo Winter Wonderland Best Ideas Virtual Conference
- GARDEN CITY, NY, Feb. 03, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH), a diversified biotech and genomics company, announces today that Chairman and CEO Ted Karkus will present at the MicroCap Rodeo Winter Wonderland Best Ideas Conference, which is being held virtually from February 8 – 11, 2022.
- 02/03/2022
|
ProPhase Labs' (PRPH) CEO Ted Karkus on Q3 2021 Results - Earnings Call Transcript
- ProPhase Labs' (PRPH) CEO Ted Karkus on Q3 2021 Results - Earnings Call Transcript
- 11/12/2021
|
ProPhase Labs to Present at the Q4 Investor Summit Conference
- GARDEN CITY, NY, Nov. 10, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH), a diversified biotech and genomics company, announces today that Chairman and CEO Ted Karkus will present at the Q4 Investor Summit Conference, which is being held virtually from November 16 – 17, 2021.
- 11/10/2021
|
ProPhase Labs to Host Third Quarter 2021 Financial Results Conference Call on Friday, November 12, 2021 at 11:00 a.m. Eastern Time
- GARDEN CITY, NY, Nov. 05, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified biotech and genomics company, will hold a conference call on Friday, November 12, 2021 at 11:00 a.m. Eastern time to discuss its results for the third quarter ended September 30, 2021. A press release detailing these results will be issued prior to the call.
- 11/05/2021
|
As Employer Vaccine Mandates Fail, Prophase Labs Could Benefit
- As Employer Vaccine Mandates Fail, Prophase Labs Could Benefit
- 10/20/2021
|
ProPhase Labs Provides Business Update
- Garden City, NY, Oct. 13, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified biotech and genomics company, today announces that it expects its Q3 2021 COVID-19 testing revenues to be lower than its Q2 2021 testing revenues given the overall lower levels of COVID-19 testing during the summer months. However, based on the recent uptick in COVID-19 testing (due in part to various government and employer-imposed mandates) and the Company's growing customer base for testing services, the Company anticipates Q4 2021 COVID-19 testing revenues to be in-line the record levels achieved in Q1 of this year, despite recently decreasing COVID-19 positivity rates.
- 10/13/2021
|
ProPhase Labs to Present at the LD Micro Main Event Conference
- GARDEN CITY, NY, Oct. 06, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH), a diversified biotech and genomics company, announces today that Chairman and CEO Ted Karkus will be presenting virtually at the 14th Annual LD Micro Main Event Conference.
- 10/06/2021
|
ProPhase Labs to Present at Two Upcoming August Conferences
- GARDEN CITY, NY, Aug. 16, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH), a diversified biotech and genomics company, today announced that Chairman and CEO Ted Karkus is scheduled to present at the following investor conferences:
- 08/16/2021
|
ProPhase Labs' (PRPH) CEO Ted Karkus on Q2 2021 Results - Earnings Call Transcript
- ProPhase Labs' (PRPH) CEO Ted Karkus on Q2 2021 Results - Earnings Call Transcript
- 08/14/2021
|
ProPhase Labs Announces Financial Results for the Quarter Ended June 30, 2021
- Company Provides Update on Significant Resurgence in Covid testing and Additional Insights into Previously Announced Nebula Genomics Acquisition
- 08/13/2021
|
ProPhase Labs to Host Second Quarter 2021 Financial Results Conference Call on Friday, August 13, 2021 at 11:00 a.m. Eastern Time
- GARDEN CITY, NY , Aug. 09, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, will hold a conference call on Friday, August 13, 2021 at 11:00 a.m. Eastern time to discuss its results for the second quarter ended June 30, 2021. A press release detailing these results will be issued prior to the call.
- 08/09/2021
|
ProPhase Labs to Present at the Access to Giving Virtual Investor Conference on July 15, 2021
- GARDEN CITY, NY, July 12, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH) (“ProPhase” or the “Company”), a diversified medical science and technology company, today announced that Chief Executive Officer Ted Karkus will present a corporate overview at the Access to Giving Virtual Investor Conference being held on July 13 - 15, 2021.
- 07/12/2021
|
ProPhase Labs Is A Potential Pure Play On Worries About The Delta And Delta Plus Covid-19 Variants
- There is concern that new Covid-19 variants are spreading and that they have the possibility to escape current vaccinations.
- 06/28/2021
|
ProPhase Labs Diversifies with Formation of Genomics and Global Healthcare Subsidiaries
- ProPhase Precision Medicine, Inc. and ProPhase Global Healthcare , Inc. to Expand Opportunities in Genomics and International Testing Services
- 06/10/2021
|
ProPhase Labs to Present at LD Micro Invitational XI Virtual Conference
- CEO Ted Karkus to Present at Conference on Thursday , June 10 th , 2021
- 05/28/2021
|
ProPhase Labs' (PRPH) CEO Ted Karkus on Q1 2021 Results - Earnings Call Transcript
- ProPhase Labs' (PRPH) CEO Ted Karkus on Q1 2021 Results - Earnings Call Transcript
- 05/13/2021
|
PRPH Stock: 14.94% Increase (From $5.22 To $6) Pre-Market Explanation
- The stock price of ProPhase Labs Inc (NASDAQ: PRPH) increased 14.94% (from $5.22 to $6) pre-market. This is why it happened.
- 05/06/2021
|
ProPhase Labs to Host First Quarter 2021 Financial Results Conference Call on Thursday, May 13, 2021 at 4:30 p.m. Eastern Time
- GARDEN CITY, NY, April 15, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, will hold a conference call on Thursday, May 13, 2021 at 4:30 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2021. A press release detailing these results will be issued prior to the call.
- 04/15/2021
|
ProPhase Labs, Inc. (PRPH) CEO Ted Karkus on Q4 2020 Results - Earnings Call Transcript
- ProPhase Labs, Inc. (PRPH) CEO Ted Karkus on Q4 2020 Results - Earnings Call Transcript
- 03/31/2021
|
ProPhase Labs Reports Fourth Quarter and Full Year 2020 Financial Results
- Recent Acquisition of Digital COVID-19 Vaccination and Testing “Passport” Transforms the Company's Portal Into a Universal Digital Certificate Solution and Uniquely Positions Company for Re-Opening Phase of Pandemic
- 03/31/2021
|
PRPH Stock Price Increased Over 10% Pre-Market: Why It Happened
- The stock price of ProPhase Labs, Inc. (NASDAQ: PRPH) increased by over 10% pre-market. This is why it happened.
- 03/31/2021
|
ProPhase Labs Acquires Digital Covid Vaccination and Testing “Passport” Solution
- New Reporting App Simplifies Documentation of User Vaccination and Covid Testing Statue – Easily Enables Clear Access to Air/Rail/Bus Travel, Concert & Sporting Events
- 03/30/2021
|
ProPhase Labs to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Wednesday, March 31, 2021 at 4:30 p.m. Eastern Time
- GARDEN CITY, NY, March 15, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, will hold a conference call on Wednesday, March 31, 2021 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2020. A press release detailing these results will be issued prior to the call.
- 03/15/2021
|
With Pivot To COVID-19 Testing, ProPhase Labs Could Greatly Reward Shareholders
- With Pivot To COVID-19 Testing, ProPhase Labs Could Greatly Reward Shareholders
- 02/17/2021
|
ProPhase Labs: Meet the team that's looking to revolutionize coronavirus testing
- ProPhase Labs, Inc (NASDAQ:PRPH) is one of three emerging companies that will present at Proactive's virtual investor conference on Tuesday, February 16. Hosted by Proactive's Christine Corrado, the event kicks off on Tuesday at 1 PM ET.
- 02/11/2021
|
ProPhase Labs Begins Advanced, Saliva-based Viral PCR Multiplex-Testing for COVID-19, Influenza A & B, and Other Viruses After FDA Confirmation of Two Emergency Use Authorizations
- Company Integrates Spectrum Solutions™ SDNA-1000 Saliva Collection System for Advanced, Simultaneous Multi-Viral Detection of Infections and Viral Mutations
- 02/09/2021
|
ProPhase Labs Exceeding Initial Goals as Covid-19 Lab Testing Business Ramps up
- Company to Host Business Update Shareholder's Conference Call on February 10, 2021 at 11:00 a.m. Eastern Time
- 02/01/2021
|
ProPhase Labs Announces Opening of Large CLIA Lab Covid Testing Facility in Garden City, New York
- - Total Company Processing Capacity On Track to Reach 60,000 Tests Per Day –
- 01/29/2021
|
ProPhase Labs, Inc. Announces Closing of Public Offering
- Garden City, NY, Jan. 21, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, today announced the closing of its previously announced public offering of 3,000,000 shares of its common stock at a public offering price of $12.50 per share, for gross proceeds of $37,500,000, before deducting underwriting discounts and commissions and offering expenses. In addition, ProPhase Labs, Inc. has granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock to cover over-allotments, if any, at the public offering price, less underwriting discounts and commissions.
- 01/21/2021
|
ProPhase Labs Announces Pricing of Public Offering of Common Stock
- GARDEN CITY, NY, Jan. 18, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, announced today the pricing of an underwritten public offering of 3,000,000 shares of common stock at an offering price of $12.50 per share, for gross proceeds of $37,500,000. In addition, ProPhase has granted the underwriters a 30-day option to purchase up to an additional 450,000 shares to cover over-allotments, if any. All of the shares are being offered by ProPhase.
- 01/18/2021
|
ProPhase Labs Announces Proposed Public Offering of Common Stock
- GARDEN CITY, NY, Jan. 15, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, announced today that it has commenced a proposed underwritten public offering of its common stock.
- 01/15/2021
|
ProPhase Labs to Present at the NobleCon17 Annual Small & Microcap Investor Conference on Tuesday, January 19, 2021 at 12:45 p.m. Eastern Time
- Company Exceeding Near Term Goals & Expands 2021 Testing Capacity
- 01/11/2021
|
ProPhase Labs Announces $5.5 Million Registered Direct Offering of Common Stock and Warrants
- GARDEN CITY, NY, Jan. 05, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, today announced that it has entered into a definitive securities purchase agreement with certain institutional and accredited investors to purchase, in a registered direct offering, 550,000 shares of ProPhase common stock, at a purchase price of $10.00 per share, together with warrants to purchase 275,000 shares of ProPhase common stock at a purchase price of $11.00 per share. Subject to customary closing conditions, the transaction is expected to close on Thursday, January 7, 2021.
- 01/05/2021
|
ProPhase Labs Expands COVID-19 Testing Capacity with New 25,000 Square Feet Testing Facility in Garden City, New York
- Company Expands to Meet Anticipated Demand for Increased Molecular Testing From New Business Opportunities – Aiming For Capacity to Process 50,000 Tests per Day
- 12/08/2020
|
ProPhase Labs Reports Financial Results for the Three and Nine Months Ended September 30, 2020
- DOYLESTOWN, Pennsylvania, Nov. 16, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, today announced net sales of $3.8 million for the three months ended September 30, 2020, compared to net sales of $2.8 million for the three months ended September 30, 2019. The Company incurred a net loss from continued operations for the three months ended September 30, 2020 of $569,000, or ($0.05) per share, compared to a net loss from continued operations of $428,000, or ($0.04) per share, for the three months ended September 30, 2019. For the three months ended September 30, 2020, the Company also recognized income from discontinued operations of $161,000, or $0.01 per share. The Company incurred a net loss for the three months ended September 30, 2020 of $408,000, or ($0.04) per share, compared to a net loss of $428,000, or ($0.04) per share, for the three months ended September 30, 2019.
- 11/16/2020
|
ProPhase Labs to Present at the Virtual Fall Investor Summit on Monday, November 16, 2020 at 2:30 p.m. Eastern Time
- DOYLESTOWN, PA , Nov. 10, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase Labs”), a diversified medical science and technology company, today announced that management will present at the Virtual Fall Investor Summit taking place November 16th – 18th, 2020.
- 11/10/2020
|
